Compare Alibaba Group (BABA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Merck & Co., Inc. — how do they compare? Alibaba Group trades at $120.53 (market cap $270.95B), while Merck & Co., Inc. trades at $123.1 (market cap $298.31B). The key difference: Alibaba Group and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| BABA | MRK | |
|---|---|---|
Market Cap | $270.95B | $298.31B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $129.52 |
52-Week Low | $94.83 | $77.60 |
Enterprise Value | $265.77B | $341.72B |
Dividend Yield | 0.93% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $112.35, up 0.02% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with robust fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 17.36 appear reasonable. The stock faces headwinds from securities investigations but benefits from AI-driven optimism in cloud growth.
Outlook remains positive given Wall Street's $195 price target and 86% buy ratings, though risks include legal overhangs and earnings volatility. AI and cloud initiatives offer growth catalysts, but investors should monitor regulatory developments and quarterly execution against expectations.
Merck (MRK) trades at $124.34, showing modest daily gains of 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 73.91% gross margins and has beaten earnings expectations in recent quarters. Recent acquisition activity, including the Terns Pharmaceuticals deal announced April 7, 2026, demonstrates strategic pipeline expansion in oncology.
Merck presents a compelling investment case with analyst consensus favoring bullish sentiment (67.57% buy ratings) and a $137.30 price target offering ~10% upside. However, rising debt levels and projected 2026 earnings decline warrant caution. The stock's premium valuation at 34x P/E requires sustained execution to justify current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
